Patents by Inventor Ditte Riber

Ditte Riber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLUCAGON ANALOGUES
    Publication number: 20160304576
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain without affecting glycemic control. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: June 27, 2016
    Publication date: October 20, 2016
    Inventors: Eddi MEIER, Ditte RIBER, Jens Rosengren DAUGAARD, Marie SKOVGAARD
  • Glucagon-like-peptide-2 (GLP-2) analogues
    Patent number: 9453064
    Abstract: GLP-2 analogs are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an altered GLP-1 activity, and their medical use. The analogs are particularly useful for the prophylaxis, treatment or ameliorating of the gastro-intestinal associated side effects of diabetes.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: September 27, 2016
    Assignee: Zealand Pharma A/S
    Inventors: Rasmus Just, Kirsten Lindegaard Bovbjerg, Ditte Riber, Wayne Shaun Russell
  • GLUCAGON-GLP-1-GIP TRIPLE AGONIST COMPOUNDS
    Publication number: 20160257729
    Abstract: The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.
    Type: Application
    Filed: November 6, 2014
    Publication date: September 8, 2016
    Applicant: Zealand Pharma A/S
    Inventors: Rasmus JUST, Ditte RIBER, Anne Pernille Tofteng SHELTON, Torbenä ØSTERLUND, Kate HANSEN, Lene JESSEN
  • Glucagon analogues
    Patent number: 9403894
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain without affecting glycemic control. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the glucagon-like peptide-1 (GLP-1) receptor as compared to human glucagon.
    Type: Grant
    Filed: June 23, 2011
    Date of Patent: August 2, 2016
    Assignee: Zealand Pharma A/S
    Inventors: Eddi Meier, Ditte Riber, Jens Rosengren Daugaard, Marie Skovgaard
  • ACYLATED GLUCAGON ANALOGUES
    Publication number: 20160120951
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: September 2, 2015
    Publication date: May 5, 2016
    Inventors: Ditte RIBER, Eddi MEIER, Jens Rosengren DAUGAARD, Marie SKOVGAARD, Jakob Lind TOLBORG, Gita KAMPEN, Camilla Ærteberg BÆk
  • GLUCAGON ANALOGUES
    Publication number: 20160009777
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: September 24, 2015
    Publication date: January 14, 2016
    Inventors: Jakob Lind TOLBORG, Keld FOSGERAU, Pia NØRREGAARD, Rasmus JUST, Ditte RIBER, Dieter Wolfgang HAMPRECHT, Robert AUGUSTIN, Leo THOMAS, Wolfgang RIST
  • COMBINATION OF ACYLATED GLUCAGON ANALOGUES WITH INSULIN ANALOGUES
    Publication number: 20160000883
    Abstract: The invention relates to methods for treating metabolic disorders, including diabetes by using a combination of an acylated glucagon analogue and an insulin analogue. The invention also features a kit that includes an acylated glucagon analogue and an insuline analogue.
    Type: Application
    Filed: September 17, 2015
    Publication date: January 7, 2016
    Inventors: Keld FOSGERAU, Ditte RIBER
  • GLUCAGON ANALOGUES
    Publication number: 20150376257
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain and for treating diabetes and associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptide compounds effective in such methods. The compounds may mediate their effect by having, for example, increased selectivity for the GLP-1 receptor compared to human glucagon.
    Type: Application
    Filed: September 14, 2015
    Publication date: December 31, 2015
    Inventors: Ditte RIBER, Eddi MEIER
  • Glucagon analogues
    Patent number: 9180169
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: November 10, 2015
    Assignee: Zealand Pharma A/S
    Inventors: Jakob Lind Tolborg, Keld Fosgerau, Pia Nørregaard, Rasmus Just, Ditte Riber, Dieter Wolfgang Hamprecht, Robert Augustin, Leo Thomas, Wolfgang Rist
  • Glucagon analogues
    Patent number: 9169310
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain and for treating diabetes and associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptide compounds effective in such methods. The compounds may mediate their effect by having, for example, increased selectivity for the GLP-1 receptor compared to human glucagon.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: October 27, 2015
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Eddi Meier
  • GIP-GLP-1 DUAL AGONIST COMPOUNDS AND METHODS
    Publication number: 20150299281
    Abstract: The present invention relates to truncated GIP analogues which comprise one or more substitutions as compared to wild-type GIP and which may have the property of an altered, preferably increased GLP-1 activity, e.g. as assessed in in vitro efficacy assays. The invention provides GIP-GLP-1 dual agonist compounds and associated methods.
    Type: Application
    Filed: May 3, 2013
    Publication date: October 22, 2015
    Inventors: Rasmus JUST, Ditte RIBER, Anne Pernille Tofteng SHELTON, Torben ØSTERLUND, Kate HANSEN, Lene JESSEN
  • Acylated glucagon analogues
    Patent number: 9156901
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: October 13, 2015
    Inventors: Ditte Riber, Eddi Meier, Jens Rosengren Daugaard, Marie Skovgaard, Jakob Lind Tolborg, Gita Kampen, Camilla Ærteberg Bæk
  • GLUCAGON ANALOGUES
    Publication number: 20150210744
    Abstract: The present invention relates to glucagon analogues and their medical use, for example in the treatment of hypoglycaemia. In particular, the present invention relates to stable glucagon analogues suitable for use in a liquid formulation.
    Type: Application
    Filed: July 23, 2013
    Publication date: July 30, 2015
    Applicant: Zealand Pharma A/S
    Inventors: Ditte Riber, Lise Giehm
  • GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES
    Publication number: 20150125431
    Abstract: GLP-2 analogues are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an altered GLP-1 activity, and their medical use. The analogues are particularly useful for the prophylaxis, treatment or ameliorating of the gastro-intestinal associated side effects of diabetes.
    Type: Application
    Filed: May 3, 2013
    Publication date: May 7, 2015
    Inventors: Rasmus Just, Kirsten Lindegaard Bovbjerg, Ditte Riber, Wayne Shaun Russell
  • GLUCAGON ANALOGUES
    Publication number: 20150111817
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: October 16, 2014
    Publication date: April 23, 2015
    Inventors: Ditte RIBER, Jakob Lind TOLBORG, Dieter Wolfgang HAMPRECHT
  • ACYLATED GLUCAGON ANALOGUES
    Publication number: 20150111826
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: October 17, 2014
    Publication date: April 23, 2015
    Inventors: Ditte RIBER, Jakob Lind TOLBORG, Dieter Wolfgang HAMPRECHT, Wolfgang RIST
  • GLUCAGON ANALOGUES
    Publication number: 20150080295
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: March 3, 2014
    Publication date: March 19, 2015
    Applicant: Zealand Pharma A/S
    Inventors: Eddi MEIER, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard
  • GHRELIN ANALOGUES
    Publication number: 20150018518
    Abstract: The present invention relates, inter alia, to ghrelin analogues and their medical use, for example in the treatment of cachexia, chronic obstructive pulmonary disease, gastrointestinal disorders (e.g., gastroparesis and/or inflammatory disorders such as colitis, gut barrier dysfunction, and ischemia reperfusion injury), loss of body weight, and decreased appetite.
    Type: Application
    Filed: February 1, 2013
    Publication date: January 15, 2015
    Applicant: ZEALAND PHARMA A/S
    Inventors: Simon Birksø Larsen, Ditte Riber
  • GLUCAGON ANALOGUES
    Publication number: 20140127175
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: January 7, 2014
    Publication date: May 8, 2014
    Inventors: Eddi MEIER, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard
  • GLUCAGON ANALOGUES
    Publication number: 20140127174
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: January 7, 2014
    Publication date: May 8, 2014
    Inventors: Eddi MEIER, Ditte Riber, Marie Skovgaard, Bjarne D. Larsen, Jens R. Daugaard, Trine S. R. Neerup